Drugs / ATB1651
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05089409 | Mar 2022 → Jun 2023 | tinea unguium | AmtixBio Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06327295 | Jul 2024 → Jun 2025 overdue | tinea unguium | AmtixBio Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATB1651 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06327295 ↗ |
| Route | Topical | “multiple doses of ATB1651 applied to 1 affected great toenail” NCT05089409 ↗ |